While p53 mutations are prevalent in ~70% of adenocarcinomas [42,43] and nearly all squamous cell carcinomas, testing for this mutation is not typically included in the diagnostic algorithm for differentiating adenocarcinoma and SCC, however it can have prognostic significance [44]. Here, TP53 is linked to adenocarcinoma.